In a hospital-based case-control study of 196 adults aged 40-75 with type 2 diabetes in South Ethiopia (98 who suffered a first cardiovascular event, mostly stroke at 43.9% and myocardial infarction at 35.7%, and 98 age- and sex-matched controls), guideline-directed statin therapy was associated with markedly lower odds of cardiovascular events (adjusted OR 0.242, 95% CI 0.093-0.630). Only 13.8% received guideline-concordant therapy, and annual lipid testing was documented in 4.6%.
The direction of the association fits decades of randomized evidence, including CARDS and the Cholesterol Treatment Trialists' meta-analyses, which show roughly a 20-25% relative reduction in major vascular events per 1 mmol/L LDL-C lowering in diabetes. An odds ratio of 0.24 is far larger than trials would predict, which is a red flag for confounding rather than a true effect size. Patients who get appropriate statins likely differ in health-seeking behaviour, access to care, adherence and blood pressure control, and retrospective record review with a single-hospital sample and a wide confidence interval (0.09-0.63) limits precision. Case-control timing also blurs whether statin use preceded events. The more actionable finding is the practice gap: fewer than one in seven patients received concordant therapy and almost none had routine lipid monitoring. For adults with type 2 diabetes anywhere, the practical message is to ask a clinician about statin eligibility and lipid testing. Confirmatory in direction, and useful mainly as a care-gap audit from an underrepresented setting.